Share on StockTwits

Regeneron Pharmaceuticals (NASDAQ:REGN) VP Douglas S. Mccorkle unloaded 5,875 shares of Regeneron Pharmaceuticals stock on the open market in a transaction dated Monday, August 18th. The stock was sold at an average price of $353.00, for a total transaction of $2,073,875.00. Following the transaction, the vice president now directly owns 3,000 shares in the company, valued at approximately $1,059,000. The transaction was disclosed in a filing with the SEC, which is available at this link.

Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 0.08% on Wednesday, hitting $346.516. The stock had a trading volume of 131,309 shares. Regeneron Pharmaceuticals has a 52-week low of $227.97 and a 52-week high of $353.05. The stock’s 50-day moving average is $319.2 and its 200-day moving average is $309.6. The company has a market cap of $34.787 billion and a P/E ratio of 98.69.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, August 5th. The company reported $2.47 earnings per share for the quarter, beating the analysts’ consensus estimate of $2.30 by $0.17. The company had revenue of $666.00 million for the quarter, compared to the consensus estimate of $647.99 million. During the same quarter last year, the company posted $1.73 earnings per share. Regeneron Pharmaceuticals’s revenue was up 45.4% compared to the same quarter last year. On average, analysts predict that Regeneron Pharmaceuticals will post $10.14 earnings per share for the current fiscal year.

A number of research firms have recently commented on REGN. Analysts at RBC Capital raised their price target on shares of Regeneron Pharmaceuticals from $349.00 to $373.00 in a research note on Wednesday, August 6th. They now have an “outperform” rating on the stock. Separately, analysts at Roth Capital reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, August 5th. Finally, analysts at Deutsche Bank raised their price target on shares of Regeneron Pharmaceuticals from $410.00 to $425.00 in a research note on Tuesday, August 5th. They now have a “buy” rating on the stock. Five investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $345.94.

Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.